Dermatologic events from EGFR inhibitors: the issue of the missing patient voice

被引：0
|
作者：
Bernd Tischer
Renate Huber
Matthias Kraemer
Mario E. Lacouture
机构：
[1] Kantar Health,Dermatology Service, Department of Medicine
[2] Merck KGgA,undefined
[3] Memorial Sloan Kettering Cancer Center,undefined
来源：
Supportive Care in Cancer | 2017年 / 25卷
关键词：
Dermatologic adverse events; EGFR inhibitors; Health-related quality of life; Skin rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：651 / 660
页数：9
相关论文
共 50 条
  • [31] Development of patient information "EGFR-inhibitors induced skin reactions"
    Boers, C.
    EJC SUPPLEMENTS, 2007, 5 (04): : 443 - 443
  • [32] Economic impact associated with the management of dermatologic adverse drug reactions (dADRs) induced by EGFR inhibitors (EGFRIs) in lung cancer
    Abraham, T.
    Rademaker, A.
    Ortiz, S.
    Bennett, C. L.
    Richey, E.
    Nonzee, N. J.
    West, D. P.
    Patel, J. D.
    Lacouture, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Combination of EGFR and COX-2 inhibitors in breast cancer patient
    Wiwanitkit, Viroj
    TUMOR BIOLOGY, 2012, 33 (04) : 1261 - 1261
  • [34] Clinical experience of chinese herbal medicine ameliorates dermatologic events from epidermal growth factor receptor inhibitors for lung cancer: A case series
    Hung, Yu-Chiang
    Chin, Chieh-Ying
    Lee, Yi-Chiao
    Chen, Yen-Hao
    Tsai, Ming-Yen
    EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2019, 15 (05) : 363 - 370
  • [35] Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel
    Cury-Martins, Jade
    Mendes Eris, Adriana Pessoa
    Zugaib Abdalla, Cristina Martinez
    Silva, Giselle de Barros
    Torel de Moura, Veronica Paula
    Sanches, Jose Antonio
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2020, 95 (02) : 221 - 237
  • [36] In this issue: The patient voice, clinical research, clustered data, and the Wonca research conference
    Stange, KC
    Miller, WL
    ANNALS OF FAMILY MEDICINE, 2004, 2 (03) : 194 - 197
  • [37] Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
    Lacouture, Mario E.
    Sibaud, Vincent
    Anadkat, Milan J.
    Kaffenberger, Benjamin
    Leventhal, Jonathan
    Guindon, Kathleen
    Abou-Alfa, Ghassan
    ONCOLOGIST, 2021, 26 (02): : E316 - E326
  • [38] Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis
    Chen, Bai-lin
    Huang, Shan
    Dong, Xiao-wan
    Wu, Dou-dou
    Bai, Yan-ping
    Chen, Yuan-yuan
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [39] ASSESSMENT OF PATIENT CHARACTERISTICS AND TYPES OF DERMATOLOGIC ADVERSE EVENTS ASSOCIATED WITH DIMINISHED QUALITY OF LIFE IN CANCER PATIENTS
    Balagula, Y.
    Hensley, J.
    Gordon, J.
    Kwasny, M.
    West, D. P.
    Lacouture, M. E.
    ANNALS OF ONCOLOGY, 2010, 21 : 34 - 34
  • [40] Qualification for TKI-EGFR inhibitors treatment in a patient diagnosed with adenocarcinoma of the lung with activating mutation in EGFR gene
    Mandziuk, Slawomir
    Wojcik-Superczynska, Magdalena
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : G14 - G16
12345